NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
RICHMOND, Calif., May 11, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced the company plans to participate in the B. Riley & Co. Institutional Investor Conference in Santa Monica, California.
Ekso Bionics’ management is scheduled to present Wednesday, May 24, 2017 at 10:00 a.m. PDT. A live and archived webcast of the presentation will be available on the investors section of the company’s website at: www.eksobionics.com.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 [email protected] Investor Contact: Debbie Kaster 415-937-5403 [email protected]
